Sign in Subscribe
Non-small cell lung cancer

Immunotherapy Compliance in Non-Small Cell Lung Cancer: Study Reveals Challenges and Opportunities

Strategic Insights

— 1 min read

According to a recent systematic review and meta-analysis, compliance with immunotherapy protocols in non-small-cell lung cancer (NSCLC) remains a significant challenge, particularly in adjuvant and perioperative settings. The study, conducted by a team of researchers from the Department of Cardio-Thoracic and Vascular Surgery at Azienda Ospedaliera-Universitaria Citta della Salute e della Scienza di Torino in Turin, Italy, aimed to evaluate compliance rates with immunotherapy-based protocols in neoadjuvant, adjuvant, and perioperative settings for resectable NSCLC.

Key Takeaways:

  • The study included 30 prospective clinical trials involving over 10,493 patients, with 26 studies investigating immunotherapy alone or in combination with chemotherapy in neoadjuvant settings.
  • In neoadjuvant settings, nearly all patients received at least one therapy administration, while 11.3% experienced incomplete cycles, and 16.1% of cases did not undergo surgery.
  • The overall protocol compliance was superior in neoadjuvant protocols (effect size: 0.78 [IC 95%: 0.70-0.85]) compared to adjuvant protocols (effect size: 0.61 [IC 95%: 0.53-0.69]) and perioperative protocols (effect size: 0.49 [IC 95%: 0.43-0.55]).
  • However, perioperative protocols showed similar compliance and Grade 3 AE rates compared to preoperative and postoperative protocols.
  • Improving protocol compliance through tailored strategies and multidisciplinary coordination is essential to maximize the therapeutic potential of immunotherapy in resectable NSCLC and enhance patient outcomes.

Statistics:

  • The study included 30 prospective clinical trials involving over 10,493 patients.
  • In neoadjuvant settings, 26 studies investigated immunotherapy alone or in combination with chemotherapy.
  • 11.3% of patients experienced incomplete cycles of immunotherapy.
  • 16.1% of cases did not undergo surgery.
  • The overall protocol compliance rate was 80.5% in neoadjuvant settings.
  • The effect size for protocol compliance in neoadjuvant settings was 0.78 (IC 95%: 0.70-0.85).
  • 67.7% of patients experienced Grade 3 adverse events (AEs) in neoadjuvant settings.
  • 19.0% of patients experienced Grade 3 AEs in adjuvant settings.

Sources:

  • Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials. Lung Cancer, 2025;209:108760.
  • Department of Cardio-Thoracic and Vascular Surgery, Azienda Ospedaliera-Universitaria Citta della Salute e della Scienza di Torino, Turin, Italy.
  • Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Eleonora Faccioli, Giorgio Facheris, Roberto Ferrara, Alessandra Ferro, Federica Filipello, Raffaele Giusti, Carlo Greco, Marco Mammana, Daniele Mar.

Read more